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Background: The prolonged survival of individuals diagnosed with cancer has led to an increase in the number of
secondary primary malignancies. We undertook to perform a definitive study to characterize and predict prognosis of
multiple primary malignancies (MPM) involving hepatocellular carcinoma (HCC), due to the scarcity of such reports.
Methods: Clinicopathological data were analyzed for 68 MPM patients involving HCC, with 35 (target group)
underwent curative liver resection. Additional 140 HCC-alone patients with hepatectomy were selected randomly
during the same period as the control group.
Results: Of the 68 patients with extrahepatic primary malignancies (EHPM), 22 were diagnosed synchronously with
HCC, and 46 metachronously. The most frequent EHPM was nasophargeal carcinoma, followed by colorectal and
lung cancer. Univariate analysis demonstrated that synchronous (P= 0.008) and non-radical treatment for EHPM
(P< 0.001) were significant risk factors associated with poorer overall survival (OS). While, Cox modeling revealed that
the treatment modality for EHPM, but not the synchronous/metachronous determinant, was an independent factor
for OS, and that therapeutic option for HCC was an independent factor for HCC-specific OS. Moreover, no HCC-
specific overall and recurrence-free survival benefit were observed in the control group when compared with that of
the target group (P= 0.607, P= 0.131, respectively).
Conclusions: Curative treatment is an independent predictive factor for OS and HCC-specific OS, and should been
taken into account both for synchronous and metachronous patients. MPM patients involving HCC should not be
excluded from radical resection for HCC.
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Hepatocellular carcinoma (HCC) ranks as the fifth most
common tumor and third leading cause of global cancer-
related mortality [1]. The improvement in early diagnosis
and the advances in treatment, including new targeted
therapy, result to greatly improve the prognosis of HCC
patients. Consequently, there is an increasing need to con-
sider the development of multiple primary malignancies
(MPM), which may influence the treatment for HCC.* Correspondence: yuanyf@mail.sysu.edu.cn
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reproduction in any medium, provided the orAlthough the incidence of MPM has begun to rise dur-
ing the past decade, knowledge of the clinical features
and outcomes of MPM remains limited. From a clinical
viewpoint, it is important to determine whether cancer-
survivors are predisposed to suffer some specific tumor
types, and whether the prognosis of MPM patients in-
cluding HCC differ from those afflicted with liver-limited
malignancy in term of HCC-specific survival. Moreover,
subsequent malignancies may not only be attributable to
prior cancer-related treatment, but may also mirror the
impact of therapy-related factors, shared etiologies, host
immune responses, environmental exposures, and com-
bination effects of the gene-environment. Clearly, as the
treatment for the first cancer might limit therapeuticd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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formation regarding the MPM patients with HCC is
needed to facilitate the establishment of therapeutic
strategies for those patients.
To the best of our knowledge, only two papers
examined the clinicopathological factors of MPM with
more than 20 patients [2,3], who had received radical
hepatectomy for primary HCC, have been published
within the last 20 years. Although small sample-sized
studies were performed in Japan [4,5], Taiwan [6], and
Western countries [7], none of them were from Main-
land China, an area with a high incidence of HCC (> 20
annual cases per 105 people) [8]. This retrospective study
was designed to characterize MPM patients, to explore
long-term prognosis, and to investigate the impact of
extrahepatic primary malignancy (EHPM) on survival of
HCC in China.
Methods
Definition of second primary malignancy
A second primary neoplasm was defined according to
IARC (International Agency for Research on Cancer)
rules [9,10], as follows: 1. The existence of two or more
primary cancers does not depend on time; 2. Both
tumors are confined to primary sites, and no direct con-
nections between the tumors exist; 3. One tumor should
only be recognized in an organ or a pair of organs or
tissue (as defined by the code of the International Classi-
fication of Diseases (ICD)); 4. Rule 3 does not apply if
tumors in an organ are of a different histology; 5. Be
different in histological type when diagnosis of pathology
available.
Patients
Between Jan. 1989 and Apr. 2008, 68 patients
experienced MPM involving HCC in the Sun Yat-Sen
University Cancer Center, and a total of 2841 HCC-alone
patients received hepatectomy during the same period.
Among the 68 MPM patients, 35 (51.5%) underwent rad-
ical hepatectomy and were defined as the target group.
To investigate the influence of EHPM on HCC-specific
survival, 140 surgical HCC-alone patients (four times of
the target group) were randomly selected from 2841
patients as the control group. The definitions for
synchronous and metachronous (interval> 6 months) have
also been addressed in several previous studies [11-13].
HCC was noninvasively diagnosed on the basis of the
typical radiological features on ultrasonography, computed
tomography (CT), magnetic resonance imaging (MRI), and
a combination of alpha-fetoprotein (AFP) levels [14].
Positron emission tomography scan with 18 F-fluorodeoxy-
glucose was carried out since Oct 2005 in our center, which
was performed if a secondary primary cancer was
suspected, and 16 patients were found using this method.Of note, histopathology from biopsy or liver resection
remains the golden diagnostic standard. Patients who met
the diagnosis criteria of autoimmune hepatitis [15] or
cholangiocarcinoma were excluded. All the recruited
patients gave written informed consent before examination
and treatment. The study protocol was approved by the
Ethics Committee of Sun Yat-Sen University Cancer Center
and conformed to the ethical guidelines of the Helsinki
Declaration.
Overall survival (OS) was calculated between the date
of the first primary treatment and date of death or last
follow-up of either the first or the subsequent malig-
nancy. HCC-specific OS was defined as the interval from
the date of diagnosis of HCC to the patient’s death of
related HCC, or last follow-up, whileas HCC-specific
recurrence-free survival (RFS) was defined as the interval
from the date of diagnosis of HCC to the tumor recurrence
or last contact with the patient if recurrence did not occur.
Curative therapy was defined as treatment for the EHPM
with intent to cure according to different tumor classifica-
tion, e.g., surgery for colorectal, gastric, lung, esophagus,
cervical, breast, thyroid, oral, and renal cancer, or radioche-
motherapy for nasopharyngeal cancer and non-Hodgkin
lymphoma. Supportive therapy was defined a treatment
that encompassed nonspecific therapeutic factors for
tumor, such as facilitating affect expression. And the pallia-
tive treatment was an intermediate one between them.
Statistical analysis
Descriptive statistics are expressed as mean ± standard
deviation. The T-test, chi-square test or Fisher’s exact
test, where appropriate, were used for univariate compar-
isons. For univariate survival analysis, plots were
generated using the Kaplan-Meier method. A Multivari-
ate model was built to evaluate the risk associated with
prognostic parameters. Differences were considered
significant when P< 0.05. All statistical analyses were
performed using SPSS version 16.0 statistical software
package (SPSS, Inc, Chicago, IL). The study was censored
on Jul 30, 2011.
Results
Patient characteristic
Of the 68 patients, 67 (98.5%) had double cancers and 1
(1.5%) suffered from triple cancers. The most frequent site
preceding or following HCC was nasopharynx (11/68,
16.2%), followed by colorectal (10/68, 14.7%), lung (6/68,
8.8%), skin, gastric, esophagus, cervical, breast, thyroid,
oral, urinary bladder, and renal cancer as well as non-
Hodgkin lymphoma. The different tumor types and thera-
peutic option for EHPM are presented in Table 1. Of the
68 patients with EHPMs, 22 were diagnosed synchronous
with HCC, and 46 belonged to the metachronous group.
To stratify the metachronous group clearly, 35 patients








group (n = 46)
Total
(n = 68)
Head & neck 8 (36.4%) 15 (32.6%) 23 (33.8%)
nasopharynx 2 (1R 1S) * 9 (9R) 11
tonsil 1 (1C) 0 1
larynx 1 (1C) 0 1
vocal cord 1 (1S) 1 (1O) 2
mouth 0 1 (1O) 1
tongue 2 (1C1S) 1 (1O) 3
gingiva 0 1 (1O) 1
soft palate 1 (1S) 0 1
thyroid gland 0 2 (2O) 2
Digestive system 8 (36.4%) 10 (21.7%) 18 (26.5%)
esophagus 1 (1S) 4 (3O1C) 5
stomach 2 (2O) 1 (1O) 3
colorectal 5 (5O) 5 (5O) 10
Urogenital system 1 (4.5%) 5 (10.9%) 6 (8.8%)
prostate 0 1 (1O) 1
urinary bladder 1 (1O) 1 (1O) 2
kidney 0 2 (1O1C) 2
ovary 0 1 (1O) 1
Others 5 (22.7%) 16 (34.8%) 20 (29.4%)
lung 2 (1C1S) 4 (1O2C 1R) 6
breast 0 4 (4O) 4
skin 1 (1O) 4 (4O) 5
Non Hodgkin’s
lymphoma
1 (1R) † 3 (3C) 3
melanoma 0 1 (1O) 1
Soft tissue tumor 1 (1O) 0 0
* numbertreatment Treatment include: O operation; R radiotherapy; C
chemotherapy; S supportive treatment.
† The patient suffered the third primary malignancy, acute monocytic
leukemia.
Figure 1 Schematic graph showing frequency distribution of
follow-up time after diagnosis of the first primary tumor in the
prior, post and metachronous groups.
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HCC (post group). In addition, 18 patients had HCC diag-
nosed before EHPM, 12 patients had HCC and EHPM
during the same hospital admission, and the remaining 38
were diagnosed with EHPM occurring ahead of HCC, with
19 patients underwent hepatectomy.
In the entire study, 61 cancer patients were male and 7
were female. Hepatitis B surface antigen (HBsAg) was
detected in 66.2% (45/68) patients, while hepatitis C anti-
body was negative in any of the patients. Cirrhosis was
present in 75.0% (51/68) of the cases. HCC patients were
diagnosed through the following routes: 35 were diagnosed
on the basis of histology via hepatectomy, 30 by standardclinical and imaging criteria combined with AFP levels,
and 3 cases underwent biopsies following an uncertain
clinical diagnosis. As demonstrated in Figure 1, 45.7%
(21/46) of the metachronous patients experienced their
secondary cancer within 2 years of the initial cancer diag-
nosis, while 55.2% (30/46) of the patients were diagnosed
within 5 years, with a clear predominance in the prior
group. The diagnostic intervals between the two cancers
ranged from 6.5 months to 14.8 years in the metachronous
patients (51.0 ±47.4 months). No significant difference was
observed in the interval time between the post and prior
groups (51.3 ±50.4 vs. 50.2 ±37.8, P=0.946).
The median follow-up time was 7.8 years, with a range
of 3.2 to 16.1 years. During the follow-up, 32 (47.1%)
patients were still alive, while 29 (42.6%) patients died of
HCC-related causes, 4 (5.9%) of EHPM-related causes,
and 3 (4.4%) of unclear causes.
Of the 68 HCC patients with a history of EHPM, 35
underwent liver resection, 7 local ablation considering
severe cirrhosis, 14 tranarterial chemoembolization, and
11 supportive treatment. Moreover, of the 68 EHPM
patients, 54 received curative therapy for EHPM, 8
palliative therapy, and 6 supportive treatment (Table 2).
No significant difference regarding gender, age, Child-
Pugh grading, AFP, GGT level, TNM stage, and treat-
ment for HCC were observed in the synchronous and
metachronous groups (Table 2). Interestingly, the rate of
patients received radical treatment for EHPM in the
metachronous group was higher than that of the syn-
chronous group (P< 0.001, Table 2).
Univarite and multivariate analysis of prognosis
The actuarial 1-, 3-, and 5-year OS rate for 68 MPM
patients were 89.3%, 63.0%, and 51.8%, respectively. The
Table 2 Patient demographical characteristics of 68
multiple primary patients with hepatocellular carcinoma
Characteristic Total Synchronous





< 58 b 33 8 25 0.165
≥ 58 35 14 21
Gender 0.514
Male 61 21 40
Female 7 1 6
HBsAg status 0.393
Negative 23 9 14




< 25 30 13 17




< 50 23 5 18




A 49 16 33
B 19 6 13
TNM stage 0.735
I 43 14 29
II 9 2 7
III 16 6 10
Treatment for HCC 0.309
Resection 35 9 26
Ablation 7 3 4
TACE 14 4 10




Curative 54 12 42
Palliative 8 4 4
Supportive 6 6 0
HCC hepatocellular carcinoma, HbsAg Hepatitis B surface Antigen, AFP
α-fetoprotein, GGT gamma-glutamyltransferase, TNM tumor-node-metastasis,
TACE transarterial chemoembolization.
* Chi-square or Fisher’s exact test.
† Patients were divided according to the median age.
Figure 2 Comparison of Kaplan-Meier curves for overall survival
between the synchronous and the metachronous groups.
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cal patients were 75.1%, 46.3%, and 35.9%, respectively.
The difference reached significance between the meta-
chronous and synchronous patients in OS (P= 0.008,
Figure 2), but not in HCC-specific OS (P=0.360, Table 3).The effects of clinical variables on the outcome were
evaluated. Treatment options for HCC (resection), level
of GGT (≤ 50 U/L) and AFP (≤ 25 ug/L), tumor number
(solitary), vascular invasion (absent), and TNM stage
(TNM stage I) were significant factors associated with
favorable HCC-specific OS in univariate analysis (Table 3).
By multivariate analysis, only treatment for HCC
remained an independent predictor of HCC-specific OS
(Table 4). Likewise, time of appearance (synchronous/
metachronous) and treatment for EHPM were strong and
significant predictors of OS in univariate analysis
(Table 3). Finally, Cox analysis revealed the treatment for
EHPM was the independent factor in OS (Table 4).
Impact of EHPM on HCC-specific survival
To investigate the impact of EHPM on survival of HCC,
140 HCC-alone randomly selected patients were
included to compare with the 35 resected HCC patients
with EHPM. No significant differences were found be-
tween the two groups in clinicopathological features
(Table 5). Moreover, the postoperative complications
were similar in two groups (P= 0.373), which included
hemorrhage, liver failure, biliary fistula, would infection,
chest infection, and cardiac arrhythmia. There was no
postoperative death occurred within 30 days after resec-
tion in both groups. Median HCC-specific OS for the
control, and target group were 2.54 years, and 2.56 years,
respectively. There were no significant HCC-specific OS
and RFS difference between the two groups (P= 0.607,
P= 0.131, respectively, Figure 3).
Discussion
The last decade has experienced a steady increase in the
incidence of MPM [16]. With the expected survival of
oncology patients prolonged, it is no longer rare to ob-
serve a subsequent primary malignancy in long-term
Table 3 Univariate analysis of prognostic factors in term of overall survival and HCC-specific overall survival
Characteristic HCC-specific overall survival rate (%) Overall survival rate (%)
3y 5y P value 3y 5y P value
Gender 0.901 0.815
Female (n= 7) 45.5 38.4 85.7 64.3
Male (n= 61) 51.4 34.3 58.0 50.4
Age (years)* 0.441 0.612
< 58 (n= 33) 52.3 47.1 62.7 62.7
≥58 (n= 35) 40.5 27.1 59.8 41.7
HBsAg status 0.148 0.909
Negative (n= 23) 40.0 28.6 56.0 49.1
Positive (n= 45) 50.8 36.2 62.4 51.8
AFP (ug/l) 0.034 0.252
≤ 25 (n= 30) 62.9 48.4 68.9 68.9
>25 (n= 38) 32.6 27.2 54.9 39.6
GGT level (u/l) 0.040 0.073
≤ 50 (n= 23) 71.8 71.8 76.5 76.5
> 50 (n= 45) 35.9 29.4 52.9 43.8
Cirrhosis .255 0.078
No (n= 17) 65.8 65.8 85.6 66.3
Yes (n= 51) 40.9 29.5 52.9 46.8
Child-Pugh classification 0.334 0.083
A (n= 49) 50.8 39.7 64.6 59.8
B (n= 19) 36.4 27.3 48.2 32.8
Tumor size (cm) 0.865 0.537
≤5 (n= 28) 49.0 42.0 62.8 47.3
>5 (n= 40) 44.6 31.5 59.7 48.0
Multiple tumors 0.001 0.221
No (n= 49) 58.0 48.1 65.3 57.7
Yes (n= 19) 11.1 11.1 62.1 41.4
Vascular invasion 0.001 0.977
No (n= 58) 51.7 40.2 60.2 52.3
Yes (n= 10) 0 0 66.8 53.4
TNM stage <0.001 0.698
I (n= 43) 58.4 50.0 61.4 54.0
II/III (n= 25) 17.1 0 60.1 47.7
Time of appearance 0.360 0.008
Synchronous (n= 22) 34.5 23.0 25.7 25.7
Metachronous (n= 46) 50.3 40.3 72.8 61.3
Treatment for HCC <0.001† 0.160
Resection (n= 35) 71.9 52.0 64.9 64.9
Ablation (n= 8) 50.8 50.8 66.7 50.0
TACE (n= 14) 0 0 50.0 37.6
Supportive (n= 11) 0 0 40.0 26.7
Treatment for EHPM 0.067 <0.001{
Curative (n= 54) 47.3 33.2 72.4 63.4
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Table 3 Univariate analysis of prognostic factors in term of overall survival and HCC-specific overall survival (Continued)
Palliative (n= 8) 19.2 19.2 35.7 17.9
Supportive (n= 6) 11.7 11.7 0 0
HCC: hepatocellular carcinoma, HBsAg: hepatitis B surface antigen, AFP: α-fetoprotein, GGT: gamma-glutamyltransferase, TACE: transarterial chemoembolization,
EHPM: extrahepatic primary malignancy.
* Patients were divided according to the median age.
† Resection vs. Ablation P= 0.346; Ablation vs. TACE P< 0.001; TACE vs. Supportive P=0.413.
{ Radical vs. Palliative P< 0.001; Palliative vs. Supportive P=0.122.
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genesis [17,18]. A recently published paper provided by
the Surveillance, Epidemiology and End Results Program
estimated 7.9% of cancer-survivors were living with a
history of more than one primary malignancy in the U. S
[16]. The reported prevalence estimated that cancer-sur-
vivors were at an increased risk of being diagnosed with
a secondary primary malignancy [19-21]. Bhatia et al.
showed the risk of second tumor was increased approxi-
mately 18 times in survivors of childhood Hodgkin’s
lymphoma [21]. The incidence of second neoplasm in
cancer-survivors (2.3%, 68/2909) of our center was in
accordance with previous literature [6,16,22,23], which
was higher than that of the normal population [1]. We
hypothesized that the improvement in early screening
technologies, the advent of new molecular targeted
agents, and elevated risk of carcinogenesis during the
anti-cancer therapy yielded an increase prevalence of
second cancer in the individuals ever diagnosed
malignancy.
Several studies have demonstrated that the risk factors
for poor survival of MPM patients, including male,
elderly, and tumor stage [11,24]. While, our study
showed no statistical difference for OS was observed in
conventional clinicopathological parameters, which was
agreed with other studies [5,23]. This discrepancy may
be due to the different disease etiologies and heterogen-
eity of study populations. We believe that a study of
patients from a large, multicenter, and multigeographic
area would reach conclusions more powerful.Table 4 Multivariate analysis of prognostic factors in term of
Characteristic HCC-specific overall surviva
P value HR (95
AFP level 0.610 1.257 (0.5
GGT level 0.449 1.485 (0.5
Tumor number 0.174 2.151 (0.7
Vascular invasion 0.148 2.550 (0.7
TNM stage 0.250 2.016 (0.6
Treatment for HCC 0.001 1.893 (1.2
Time of appearance -
Treatment for EHPM -
HCC: hepatocellular carcinoma, AFP: α-fetoprotein, GGT: gamma-glutamyltransferase
Hazard ratio, CI: confidence interval.A unimodal distribution of interval time among the
prior and post subgroups of the metachronous group
was shown in Figure 1. Based on the time since the first
cancer diagnosis, the overall risk was decreased following
the first 2 years. Considering that most secondary can-
cers were detected by periodic examination, a postopera-
tive periodic checkup should be performed intensively
both for the prior and post groups, especially during the
first 2 years. Interestingly, we found that an obvious pre-
dominance exhibited in the prior group. We hypothe-
sized that the poor prognosis of HCC may explain
partially to this circumstance [25].
Information regarding the common sites of EHMP
may benefit the detection of high-risk individuals via
early diagnosis, leading to improve cancer-survivor out-
come. Therefore, we analyzed the frequency of EHPM
according to tumor types. Contrary to our expectations
drawn from the results of previous studies conducted in
Japan [4] and Western countries [23], nasopharynx can-
cer ranked first in extrahepatic tumors, not gastric nor
colorectal cancer. Nasopharyngeal carcinoma (NPC) is a
disease with remarkable geographic distribution and a
high incidence rate in South China. However, despite its
prevalence, it does not rank first among extrahepatic
tumors in South China [26]. The reasons for the high in-
cidence of NPC in HCC patients are unclear. No appar-
ent environmental [27] or shared genetic factors [28]
explained the circumstance. In light of the high fre-
quency of NPC in EHPM, head and neck screening
(physical examination and flexible laryngoscopy) shouldoverall survival and HCC-specific survival
l Overall survival







- 0.535 1.329 (0.542-3.261)
- <0.001 2.758 (1.581-4.811)
, TNM: tumor-node-metastasis, EHPM: extrahepatic primary malignancy, HR:
Figure 3 Comparison of Kaplan-Meier curves between the 140
HCC-alone patients and 35 multiple primary malignancies
(MPM) patients with surgical HCC in term of HCC-specific overall
survival (A), and HCC-specific recurrence-free survival (B).
Table 5 Compared clinicalpathological features between
35 surgical HCC patients with multiple primary tumor








Age (years) * 56.3±12.6 59.1±11.2 0.317 {




AFP level (<25: ≥25)
(ng/ml)
17:18 44:96 0.057






















TNM stage (I: II: III) 26:4:5 112:18:10 0.401
Complication (No: Yes) 6:29 14:126 0.373
HCC: hepatocellular carcinoma, HBsAg: hepatitis B surface antigen, AFP: α-
fetoprotein, GGT: gamma-glutamyltransferase, TNM: tumor-node-metastasis.
* Mean ± Standard Deviation.
† Chi-square test for difference between proportions (except that of Age).
{ T test for difference between means.
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oncologists should be aware of the risk of secondary
tumor development if unexpected symptoms or signs ap-
pear, as intensive follow-up may benefit early diagnosis.
A differential diagnosis of HCC should be made, as the
liver being one of the most common sites of metastases.
In our cohort, 30 HCC patients were diagnosed via
standard clinical and imaging criteria combined with an
elevated AFP level. The characteristic of HCC imaging in
the MPMs was similar to that of HCC-alone patients.
Dynamic CT can provide useful information for the dif-
ferential diagnosis for hepatic nodules [29]. A metachro-
nous patient presented two hepatic nodules after NPC
radiotherapy in this study. CT imaging showed two
nodules with distinct radiologic natures (one with typical
presentation of a low-density mass in the plain CT,
which changed to a high-density mass in the arterial
phase with relative low density in the delayed phase of
dynamic CT; the other presented metastatic cancer: en-
hance less intensively and washout more slowly).Postoperative pathology confirmed the case suffered
hepatoma complicating hepatic metastases from NPC.
We investigated whether cancer-survivors would
experience poorer prognoses after second malignant
neoplasm diagnosed. Our study showed that the differ-
ence of HCC-specific survival between MPM involving
HCC and HCC-alone failed to reach statistical signifi-
cance. This finding was similar to that reported in
several cohorts [2,23], and reflected differences in the
natural course of HCC compared with most associated
EHPM. HCC is always associated with a poorer survival
and a more aggressive behavior than most other tumors.
Several cohort studies noted that the causes of death in
HCC patients with EHPM were mostly attributed to
HCC itself, not to extrahepatic cancer [3,5]. In light of
these data, we stressed the need to prioritize curative
treatment for HCC independently of the EHPM, as the
presence of an EHPM had little impact on HCC-specific
prognosis. While, we noticed that no significant
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surgery and other therapeutic options for HCC. A long-
term diagnostic interval time (median 32.4 months) from
the diagnosis of the first neoplasm to the subsequent
tumor presumably influenced the impact efficiency of
treatment options for HCC on overall survival.
A significant difference in OS between the patients in
the metachronous group and the synchronous group was
not surprising. Compared with metachronous patients,
synchronous patients had poorer OS. As demonstrated
in Table 3, synchronous and metachronous groups
associated with different treatment approaches for the
extrahepatic tumor, and different treatment strategies led
to distinct outcomes. Thus, we suspected that treatment
modality was the final influencing factor for overall
survival and built a Cox multivariate model for verifica-
tion. Cox analysis confirmed it and demonstrated that
treatment options for extrahepatic cancer remained as
the significant factor. Therefore, an increasing effort to
enlarge the proportion of patients undergoing radical
treatment should been taken into account, irrespective of
synchronous or metachronous tumor development.
Curative resection, if possible, most effectively
prolongs patient survival. However, in cases of HCC with
EHPM, the choice of treatment strategy should be made
carefully in conjunction with the treatment for EHPM.
There are few reports on how to treat patients with
MPM involving HCC, which remains a key challenge. In
our cohort, hepatectomy was an independent prognostic
factor associated with good outcome. In spite of the
patients that had a cirrhosis background, as experienced
in our center, when patients had well-preserved liver
function and when there was also an absence of extrahe-
patic metastasis, aggressive liver resection provided an
opportunity for long-term survival.
MPM patients including HCC were often treated with
supportive treatment, due to the limited therapeutic
options, disappointed radical surgical rate, and poor prog-
nosis of HCC [25]. Although several papers reported
MPM concomitant with surgical HCC patients [2-5,23,24],
with the small number of patients, the statistical power
was limited. Of noted, only two cohort studies investigated
the influence of EHPM on survival with more than 20
surgical HCC [2,3]. Furthermore, both of the two papers
failed to refer to HCC-specific survival, which lead to
decrease the value for clinical practice. We believe the
present study may provide powerful evidence to make
therapeutic strategy for MPM patients with HCC, which
suggest those patients should not be excluded from radical
resection for HCC.
Potential limitations of our study are the long time
span of the observed data and the relatively small sample
size, particularly with only 35 MPM patients with
resected liver tumors. It would be more powerful theresults from multicenter studies with larger numbers,
considering the different geographic distribution of
HCC. Nonetheless, the consistency of our findings with
previous clinical surveys reinforces the validity of our
conclusions.
Conclusions
In conclusion, NPC, colorectal, and lung cancers were
the tumors most frequently accompanying HCC. Careful
follow-up and active treatment is suggested for these
patients. Curative treatment should been taken into ac-
count both for synchronous and metachronous patients.
The efficiency of the treatment against HCC and EHPM
had great influence on the prognosis. Moreover, EHPM
did not confer a poorer HCC-specific survival, and those
patients should not be excluded from curative therapies.
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